M0238 Intrav inferior, toci, second dos
Also known as: toci infusion second, follow-up tocilizumab
Intravenous infusion of tocilizumab, second dose. Subsequent administration of tocilizumab following the initial dose.
In Plain Language
Second antibody therapy injection; Ongoing immune system treatment
Clinical Context
Used for subsequent intravenous administration of tocilizumab in patients continuing biologic therapy for rheumatoid arthritis or other inflammatory conditions.
RVU Information
CPT M0238 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
M-codes cover quality measures and performance reporting. They are used in value-based care programs to track whether specific clinical actions were taken. Documentation must support that the measured action was performed or a valid exclusion applies.
Specialties
Frequently Asked Questions
What is CPT code M0238?
CPT M0238 (Intrav inferior, toci, second dos) is a M Codes code. Intravenous infusion of tocilizumab, second dose. Subsequent administration of tocilizumab following the initial dose.
Is M0238 covered by insurance?
M0238 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for subsequent intravenous administration of tocilizumab in patients continuing biologic therapy for rheumatoid arthritis or other inflammatory conditions.
When is CPT M0238 used?
Used for subsequent intravenous administration of tocilizumab in patients continuing biologic therapy for rheumatoid arthritis or other inflammatory conditions.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.